NOVOZYMES A/S SPONS.ADR 1 Cash Flow Conversion Efficiency
NOVOZYMES A/S SPONS.ADR 1 cash flow conversion efficiency. Based on the latest financial reports, NOVOZYMES A/S SPONS.ADR 1 (NZM) has a cash flow conversion efficiency ratio of 0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€167.10 Million ≈ $195.36 Million USD) by net assets (€10.92 Billion ≈ $12.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NOVOZYMES A/S SPONS.ADR 1 (NZM) total market value for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
Cash flow conversion efficiency of NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025. This chart illustrates how NOVOZYMES A/S SPONS.ADR 1's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of NOVOZYMES A/S SPONS.ADR 1 for real-time trading data and today's change.
NOVOZYMES A/S SPONS.ADR 1 Cash Flow Conversion Ratio Explained
NOVOZYMES A/S SPONS.ADR 1 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NOVOZYMES A/S SPONS.ADR 1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NOVOZYMES A/S SPONS.ADR 1 ranked by their cash flow conversion efficiency. Review NZM FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fresnillo plc
F:FNL
|
0.020x |
|
Expeditors International of Washington, Inc.
NYSE:EXPD
|
0.084x |
|
NATURGY ENERGY ADR1/5/E01
F:GANA
|
0.136x |
|
InterContinental Hotels Group PLC
LSE:IHG
|
-0.215x |
|
First Citizens BancShares, Inc.
NASDAQ:FCNCA
|
0.048x |
|
Principal Financial Group Inc
NASDAQ:PFG
|
0.161x |
|
Las Vegas Sands Corp
NYSE:LVS
|
0.623x |
|
Repsol S.A
F:REPA
|
0.036x |
Annual Cash Flow Conversion Efficiency for NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025. Also see balance sheet size of NOVOZYMES A/S SPONS.ADR 1 for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €10.86 Billion ≈ $12.69 Billion |
€1.22 Billion ≈ $1.43 Billion |
0.113x | +23.31% |
| 2024-12-31 | €11.18 Billion ≈ $13.07 Billion |
€1.02 Billion ≈ $1.19 Billion |
0.091x | -68.46% |
| 2023-12-31 | €1.93 Billion ≈ $2.25 Billion |
€557.10 Million ≈ $651.31 Million |
0.289x | +2.75% |
| 2022-12-31 | €1.91 Billion ≈ $2.23 Billion |
€537.65 Million ≈ $628.57 Million |
0.282x | -15.39% |
| 2021-12-31 | €1.64 Billion ≈ $1.92 Billion |
€546.17 Million ≈ $638.53 Million |
0.333x | -- |
About NOVOZYMES A/S SPONS.ADR 1
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more